Expanded Access to Neladalkib (NVL-655) for People with Non-Small Cell Lung Cancer

Full Title

Expanded Access Treatment of Neladalkib (NVL-655) in Patients with Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Purpose

Researchers are assessing neladalkib for people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has spread beyond its original location. In addition, their cancers have a fusion (genetic change) involving a gene called ALK.

Neladalkib blocks the ALK protein, which is found in cancer cells with the ALK gene. Cancer cells need these proteins to survive and grow. Neladalkib may work well for you because it may keep working after cancer cells stop responding to similar treatments. It is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Alexander Drilon’s office at 646-608-3758.